Updated 12:17 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 58,232.43 -0.96%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $58,232 −0.96% VIX 35.89 +26.20% latest tape · as of 12:17 UTC
The Screen · Healthcare · Biotechnology

Solid Biosciences Inc

SLDB · NASDAQ · USD · Market cap $858M · 121 employees

Solid Biosciences Inc.

FAIL · Does not pass the screen
6.25 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price6.25 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.52x the price, above our 2.00x limit.
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans slightly to calls (put/call 0.96)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Accumulation ?
Screened · screened 2026-11-20
  • Trend Accumulation
  • Insiders insiders sold, $24,582, latest filing 2026-10-19
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.96, read 2026-11-19
  • Ethical does not pass the values gate
Price6.25 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-16Read Accumulation6.84-8.6% to today Distribution gives way to Accumulation after a 10% rise in 2 weeks
2026-11-01Read Distribution6.20+0.8% to today Markdown gives way to Distribution after a 30% slide in 4 weeks
2026-10-02Read Markdown8.91-29.9% to today ✓Accumulation gives way to Markdown
2026-09-13Read Accumulation8.72-28.3% to today Markup gives way to Accumulation first Accumulation read since July

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Solid Biosciences Inc holds its Accumulation at $6.25. The statistical read favours the sellers, held for 68 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateThe statistical read favours the sellers, held for 68 days
Price at the screen$6.25
ValuationN/A trailing · -4.45 forward price to earnings
Values screenFAIL · score 70.0
Beta2.36
The Workings

Five Screens: SLDB's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 9.10% Below 33% Pass
Interest-bearing cash 55.02% Below 33% Fail
Receivables 25.76% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Solid Biosciences's business is fine, but its cash and interest-bearing securities are about 55% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when SLDB's ethical verdict changes

Today SLDB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.52x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
11.00Street low 16.00Street average 26.00Street high 6.25Price

Street: 12 covering, consensus Strong Buy. Average target +156%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-4.5x
EPS, trailing-1.92
EPS, forward-1.96
Profit margin0.0%currently unprofitable
Return on equity-57.4%not currently earning a positive return on equity
FCF yield-12.93%
Debt to equity0.06minimal debt: a conservative balance sheet
Current ratio13.10comfortably covers its short-term bills
Beta2.36much more volatile than the market
Short interest, float0.21%
52-week range3.79 - 11.45
MoatNONE
Market cap$858M
Employees121

SLDB-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $6.35 -7.2% Entry 19
2026-11-16 Accumulation · changed $6.84 +3.8% Entry 18

The framework has shifted from distribution to accumulation since the last review.

2026-11-09 Distribution $6.59 +6.3% Entry 17
2026-11-02 Distribution $6.20 +0.0% Entry 16
2026-11-01 Distribution · changed $6.20 +4.7% Entry 15

The framework has shifted from markdown to distribution since the last review.

2026-10-31 Markdown $5.92 +0.0% Entry 14
2026-10-30 Markdown $5.92 +0.0% Entry 13
2026-10-29 Markdown $5.92 +8.3% Entry 12
2026-10-28 Markdown $5.47 +0.0% Entry 11
2026-10-27 Markdown $5.47 +0.0% Entry 10

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Related Securities · Others in SLDB's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · SLDB
DateInsiderTitleTypeSharesValue
2026-10-19 Brooks Gabriel Chief Medical Officer S - Sale+OE 4,374 $24,582

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $7.68 -13.9% · $861 -13.9%
2 months $8.02 -17.6% · $824 -17.6%
3 months $7.71 -14.3% · $857 -14.3%
6 months $5.87 +12.6% · $1,126 +12.6%
1 year $4.83 +36.9% · $1,369 +36.9%
2 years $7.82 -15.5% · $845 -15.5%
3 years $6.34 +4.3% · $1,043 +4.3%
5 years $61.65 -89.3% · $107 -89.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SLDB does next, these words stay.

Solid Biosciences Inc · SLDB · Accumulation · $6.25
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.